Trials / Not Yet Recruiting
Not Yet RecruitingNCT07404111
A Study of VV-14305 for the Treatment of Thyroid Eye Disease
An Adaptive Phase 1/2 MulticenteR Study Evaluating the Safety, Tolerability, Pharmacokinetics and EfficaCy of VV-14305 Delivered Via PeribuLbAr Injection in Patients With Moderate to Severe Thyroid Eye Disease (the RECLAIM Study)
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Kriya Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to evaluate the safety, tolerability, and efficacy of KRIYA-586 (VV-14305) in treating thyroid eye disease (TED).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | VV-14305 | VV-14305 will be administered via peribulbar injection. |
| OTHER | Sham (No Treatment) | Sham solution such as Saline |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2028-02-01
- Completion
- 2029-02-01
- First posted
- 2026-02-11
- Last updated
- 2026-02-11
Locations
1 site across 1 country: New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07404111. Inclusion in this directory is not an endorsement.